Ulevostinag + Pembrolizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma (HNSCC)
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Timeline
Mar 4, 2020 → Sep 30, 2022
NCT ID
NCT04220866About Ulevostinag + Pembrolizumab
Ulevostinag + Pembrolizumab is a phase 2 stage product being developed by Merck for Head and Neck Squamous Cell Carcinoma (HNSCC). The current trial status is completed. This product is registered under clinical trial identifier NCT04220866. Target conditions include Head and Neck Squamous Cell Carcinoma (HNSCC).
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Squamous Cell Carcinoma (HNSCC) were approved
Approved (11) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04220866 | Phase 2 | Completed |
| NCT03010176 | Phase 1 | Completed |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma (HNSCC)